Goldman Sachs Group Inc Actinium Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
A detailed history of Goldman Sachs Group Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 40,278 shares of ATNM stock, worth $72,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,278
Previous 11,147
261.33%
Holding current value
$72,500
Previous $87,000
242.53%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ATNM
# of Institutions
77Shares Held
7.11MCall Options Held
96.6KPut Options Held
70.5K-
Black Rock Inc. New York, NY1.88MShares$3.38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.66 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$1.2 Million0.0% of portfolio
-
State Street Corp Boston, MA610KShares$1.1 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0256KShares$460,8460.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $45.3M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...